Nuvelo starts alfimeprase PAO Phase III

NUVO began the double-blind, placebo-controlled international Phase III NAPA-2 trial of alfimeprase in about 300 patients with acute peripheral arterial occlusion (PAO). The primary endpoint is avoida...